- Home
- IBIO vs IAE Comparison
IBIO vs IAE Comparison
Compare IBIO & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBIO | IAE |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 78.2M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBIO | IAE |
|---|---|---|
| Price | $2.02 | $7.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 962.0K | 50.3K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.21% |
| EPS Growth | ★ 73.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $5.34 |
| 52 Week High | $3.82 | $8.30 |
Technical Indicators
Market Signals| Indicator | IBIO | IAE |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 46.29 |
| Support Level | $1.70 | $7.11 |
| Resistance Level | $2.82 | $7.58 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 53.37 | 51.88 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.